Floatz logo

Neratinib

PR-Positive Breast Cancer

Massachusetts General HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the PR-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Jennifer Lee Caswell-Jin
Phase 2BB
Letrozole
Ruth O'Regan
Phase 2BB
Cyclophosphamide
University of Washington
Phase 2B
FILGRASTIM
University of Washington
Phase 2B
Thiotepa
Fred Hutchinson Cancer Center
Phase 2B

View all 37 →

Same molecule, other indications

Neratinib is also rated in:

breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Metastatic Breast CarcinomaDormant
B
Indicative ·
62 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →